All In Biotech

Drug Trial Radar · NCT00492960

Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

A Phase IIb, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge

Last checked: Nov 19, 2026Latest source record: Sep 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 171 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

171

Actual

Start

Aug 2007

Primary completion

Oct 2008

Study completion Mar 2009

Sponsor

Lead sponsor
9 Meters Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Jun 27, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 72 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was conducted to evaluate the efficacy of multiple doses of larazotide acetate in preventing intestinal permeability changes induced by a 6- week gluten challenge in subjects with celiac disease.

Conditions

  • Celiac Disease

Interventions

  • larazotide acetateDrug

    gelatin capsules

  • placeboDrug

    gelatin capsules

  • 900 mg glutenDietary supplement

    gelatin capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of multiple doses larazotide acetate in preventing intestinal permeability changes induced by a 6- week gluten challenge.Time frame: Following ingestion of a solution of lactulose and mannitol; lactulose and mannitol excretion was quantified and the LAMA ratio calculated from overnight urine specimens collected on Days 7, 21, 35, 49 and 56.

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Study Site

    Scottsdale, Arizona

  • Study Site

    Colorado Springs, Colorado

  • Study Site

    Chicago, Illinois

  • Study Site

    Lexington, Kentucky

  • Study Site

    Hagerstown, Maryland

  • Study Site

    Boston, Massachusetts

  • Study Site

    Troy, Michigan

  • Study Site

    Rochester, Minnesota

  • Study Site

    New York, New York

  • Study Site

    Asheville, North Carolina

  • Study Site

    Cleveland, Ohio

  • Study Site

    Philadelphia, Pennsylvania

  • Study Site

    Pittsburgh, Pennsylvania

  • Study Site

    Houston, Texas

  • Study Site

    Plano, Texas

  • Study Site

    Richmond, Virginia

  • Study Site

    Seattle, Washington

  • Study Site

    Calgary, Canada

  • Study Site

    Montreal, Canada

  • Study Site

    Toronto, Canada

  • Study Site

    Winnipeg, Canada

  • Study Site

    Edmonton, Alberta, Canada

  • Study Site

    Kelowna, British Columbia, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.